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Natural Course
of Myoclonus-Dystonia
in Adulthood: Stable Motor Signs
But Increased Psychiatry
Myoclonus-dystonia (M-D) is a rare hyperkinetic movement
disorder characterized by upper body–predominant myoclo-
nus and dystonia.1 A large proportion of cases are caused by
autosomal-dominant inherited mutations in the SGCE gene.
In addition to the motor manifestations, psychiatric disorders
are frequently reported.2 Several studies have suggested that
they may form a primary component of the M-D pheno-
type.3,4 This study represents the first long-term follow-up
study of both motor and psychiatric symptomatology in
adults with M-D (SGCE mutation), providing further
insights into the natural history of M-D and enabling more
prognostic information.
Methods
Manifesting adult carriers with a mutation in the SGCE gene
were included, whose baseline data were collected in the
Netherlands, Belgium, and the United Kingdom and reported
previously.2,3,5
Regarding motor signs, both at baseline and follow-up,
Burk Fahn Marsden Dystonia Rating Scale (BFMDRS) and
Unified Myoclonus Rating scale (UMRS) were used to objec-
tively assess motor sign severity. Psychiatric comorbidity and
quality of life were evaluated using the same (or highly com-
parable) questionnaires at baseline and follow-up.
Results
Of the 63 adult M-D patients recruited in the original stud-
ies, 27 patients were able to participate in this follow-up
assessment. An overview of body distribution and severity
scales of motor signs at baseline and follow-up examination
can be found in Table 1. No age-distinctive pattern in the
scores was observed. See Table 1 for the prevalence of psychi-
atric disorders and scores of severity scales. No associations
between changes in motor symptoms and psychiatric symp-
tom severity, quality of life, and demographic information
were found.
TABLE 1. Demographics, motor symptoms, and psychiatric
comorbidities
Total number of patients 27
Sex M/F 11/16
Age at onset dystonia (range) 8 (1–40)
Age at onset myoclonus (range) 7 (1–17)
Oral medication for motor symptoms 6 (22%)
Antidepressant
SSRI 4 (13%)
SNRI 2 (7%)
TCA 1 (3%)
Botulinum neurotoxin injections 3 (11%)
Motor symptoms
Baseline
examination
Follow-up
examination P
Age (SD) 44.6 (14.3) 55.2 (14.4)
Number of patients with:
Dystonia 23 (85%) 25 (93%) 0.625a
Myoclonus 22 (81%) 24 (89%) 0.500a
Body distribution
Dystonia (n = 21)
— Upper limbs 5 (24%) 18 (86%) < 0.001a
— Lower limbs 2 (10%) 5 (24%) 0.250a
— Neck 18 (86%) 19 (90%) 1.000a
— Trunk 5 (24%) 8 (38%) 0.453a
Myoclonus (n = 22)
— Upper limbs 20 (91%) 20 (91%) 1.000a
— Lower limbs 1 (5%) 7 (32%) 0.070a
— Neck 8 (36%) 16 (73%) 0.008a
— Trunk 6 (27%) 15 (68%) 0.012a
All patients
BFMDRS, n = 24 (range) 3.5 (0–20) 6.6 (0–17.5) 0.203b
UMRS, n = 24 (range) 2.3 (0–12) 3.7 (0–12) 0.140b
Patients with mutation inherited via paternal line
BFMDRS, n = 19 (range) 4.0 (0–20) 7.0 (1–17.5) 0.198b
UMRS, n = 19, (range) 5.2 (0–12) 5.4 (0–12) 0.260b
Baseline
examination
Follow-up
examination
Psychiatry n = 26 n = 6 Pa
Any psychiatric
disorder
16 (62%) 20 (77%) 0.219
Depression 7 (27%) 13 (50%) 0.070
Panic disorder 6 (23%) 12 (46%) 0.031
Social phobia 6 (23%) 4 (15%) 0.688
(Continues)
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Discussion
This is the first systematic long-term follow-up study of
both motor and psychiatric manifestations in adult M-D
patients. Despite the percentage of patients retested (27 of
63), the rarity of M-D makes our results valuable. Results
of this study showed that in adulthood the course of dysto-
nia and myoclonus is static and the prevalence of psychiatric
comorbidities remains high. Specific psychiatric disorders,
notably panic disorder and depression, became even more
prevalent over time.
It appears that in adulthood severity of motor manifesta-
tions is relatively stable, but distribution lightly changed. At
follow-up examination significantly more patients had dysto-
nia in the upper limbs and more patients had myoclonus in
the neck and trunk compared with baseline. This is consistent
with previous findings.6
Comparable to the literature, psychiatric comorbidity was
highly prevalent in our cohort. The prevalence of panic disor-
der doubled at follow-up compared with baseline and was
accompanied by an increased score on the anxiety severity
scale. Similar, but not statistically significant, findings were
detected for depressive disorder. It is unlikely that our findings
are because of an increase in age, as the prevalence of panic
disorder and depression in the general population tends to
decrease in the age group of our cohort.7
The relatively stable course of motor manifestations is in
contrast with the increased prevalence of psychiatric comor-
bidity. Results highlight the need for more awareness and ade-
quate treatment for psychiatric disorders in M-D patients.
Simultaneously, adult patients can be reassured that their
motor functioning will not deteriorate.
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TABLE 1. Continued
Baseline
examination
Follow-up
examination
Psychiatry n = 26 n = 6 Pa
OCD 3 (12%) 6 (23%) 0.453
Alcohol dependence 3 (12%) 3 (12%) 1.000
GAD 3 (12%) 3 (12%) 1.000
Specific phobia 3 (14%)3 5 (23%)3 0.688
Agoraphobia 4 (33%)4 6 (50%)4 0.500
Hypomania 1 (10%)6 1 (10%)6 1.000
Psychosis 1 (10%)6 2 (20%)6 1.000
n = 22 n = 22 Pb
YBOCS (range) 0.0 (0–14) 0.0 (0–12) 0.634
BDI (range) 5.0 (0–21) 7.5 (0–30) 0.038
BAI (range) 5.0 (0–24) 7.5 (0–45) 0.070
n = 13 n = 13 Pc
QoL PC (SD) 44.8 (8.8) 45.2 (6.9) 0.875
QoL MC (SD) 38.8 (13.6) 43.0 (9.2) 0.193
The following statistical tests were used:
aMcNemar test.
bWilcoxon signed rank test.
cPaired-sample t test: 1n = 9; 2n = 5; 3n = 22; 4n = 12; 5n = 7; 6n = 10.
SSRI, selective serotonin reuptake inhibitor; SNRI, selective serotonin and
noradrenalin reuptake inhibitor; TCA, tricyclic antidepressant; BFMDRS,
Burke Fahn Marsden Dystonia Rating Scale; UMRS, Unified Myoclonus
Rating Scale; OCD, obsessive compulsive disorder; GAD, generalized
anxiety disorder; YBOCS, Yale Brown Obsessive Compulsive Scale; BDI,
Beck Depression Inventory; BAI, Beck Anxiety Inventory; QoL PC, physi-
cal component of quality of life; QoL MC, mental component of quality
of life.
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